Investing
Drugmaker Gilead to acquire CymaBay for $4.3 billion
© Reuters. FILE PHOTO: Gilead Sciences is seen in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo
(Reuters) – Gilead Sciences (NASDAQ:) on Monday said it will acquire CymaBay Therapeutics (NASDAQ:) for $4.3 billion, to expand its portfolio of liver disease drugs.
The deal will give Gilead access to CymaBay’s lead drug candidate called seladelpar for the treatment of primary biliary cholangitis, a type of chronic inflammatory liver disease.
CymaBay had submitted a marketing application to the U.S. Food and Drug Administration (FDA) for the drug in December.
Shares of CymaBay were halted ahead of the announcement in premarket hours.
Read the full article here
-
Personal Finance6 days ago
Gas prices drop as demand for driving fizzles out: AAA
-
Investing6 days ago
Crowdstrike CEO Responds to Causing Largest IT Outage in History
-
Side Hustles6 days ago
How to Build A Startup, From an Early Lyft, Twitch Investor
-
Passive Income6 days ago
The Top 5 AI Tools That Can Revolutionize Your Workflow and Boost Productivity
-
Passive Income4 days ago
NLRB Drops Expanded Joint Employer Appeal
-
Side Hustles6 days ago
Jake Paul: Mindset Hacks, Mike Tyson Fight, Embracing Fear
-
Investing7 days ago
Boeing to supply E-7 in first major win since plea deal By Reuters
-
Side Hustles5 days ago
10 Effective Growth Marketing Strategies for Your Startup